

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_80329
Title of the Manuscript:	Anti-VEGF therapy in ophthalmology
Type of the Article	Review Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

<https://www.journaljpri.com/index.php/JPRI/editorial-policy>

Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	<p>1.The purpose of the review as a specific to ocular diseases has not been clarified in the introductory part of the review. Authors should make every effort to highlight the purpose of the review in the field of Ophthalmology.</p> <p>This review article has presented as narrative review rather than a 'systematic review'. So the structure of the presentation should be rearranged for narrative review. I.e. No material methods/Discussion required. Only 3 references are provided. This number is very less to describe a review article.</p> <p>2. Page 3: There are many factors that are involved in this process and are as following.....Verify the factor PDGF.</p> <p>3.Page 3:'Hypoxia inducible factor-1 (abbreviated as HIF-1) regulates the VEGF-A via VEGFR1 which itself is oxygen dependent for being regulated'? verify the mechanism. I.e. HIF-1 regulate the transcription of VEGF gene to increase the protein level.</p> <p>4. The description under the subtitle 'VEGF' is incomplete/not specifically written. Furthermore, the numbering a,b,.....then 2 do not clarify anything. So these section need to describe about the formation of VEGF and its signaling in angiogenesis (Ref. J Basic Clin Physiol Pharmacol. 2018;30(1):11-18; Biofactors. 2009;35(4):332-37.).</p> <p>5.Page 4/2nd para:bevacizumab is an off-label drug' Correct as 'bevacizumab is an off-label drug to treat eye disease'</p> <p>6. Page 4. Title- Indications of VEGF. Delete the para about the cancer as it is not within the scope of this review.</p> <p>7. Many sentences/meaning are repeated in the introduction and discussion part of the MS.</p>	
Minor REVISION comments	<p>1. Check the spelling and grammar mistakes throughout the MS. E.g. Abstract- The implications of anti-VEGF <u>dungs</u> are cancers,..... Mechanism of angiogenesis: angiogenesis is that process.....</p> <p>2. Citation of references for many sentences based on previous findings are missing in the text. E.g. Patients .. anti-VEGF drug showed ...~19% improvement thus ... drugs are almost two times more efficient than laser therapy.</p>	
Optional/General comments		

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Ajith T A
Department, University & Country	Amala Institute of Medical Sciences, India